Name: Current Indications for PD-1/PD-L1 Immunotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Uploaded: 2021-10-04T00:00:00+00:00
Description: Head and neck cancer and skull base surgeon Nyall London discusses three key immunotherapy clinical trials including KEYNOTE-012, Checkmate 141 and KEYNOTE-048 that have contributed to Food and Drug Administration approval for nivolumab and pembrolizumab, which are PD-1 inhibitors, for recurrent head and neck squamous cell carcinoma.

Head and neck cancer and skull base surgeon Nyall London discusses three key immunotherapy clinical trials including KEYNOTE-012, Checkmate 141 and KEYNOTE-048 that have contributed to Food and Drug Administration approval for nivolumab and pembrolizumab, which are PD-1 inhibitors, for recurrent head and neck squamous cell carcinoma.

Related Presenters

Nyall London, MD, PhD

Associate Professor of Otolaryngology - Head and Neck Surgery

Dr. London was born and raised in Southern California. He received his bachelor’s degree in Microbiology from Brigham Young University followed by his M.D. Ph.D. from The University of Utah. Dr. London then completed his residency in Otolaryngology-Head ...

View full profile